ArticleIndian journal of ophthalmology2026
Indications and long-term outcomes of repeat optical penetrating keratoplasty.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the indications, practice pattern of immunomodulation (IM), and outcomes of repeat optical penetrating keratoplasty (OPK).
methodsOf 4454 OPKs performed from 2016 to 2023, 259 (5.81%) were OPK following previous failed OPKs (OPK/OPK) and these were included in the study; those with follow-up <1 m were excluded. Indications for primary, last graft, risk factors, and IM use were recorded. Hazard's ratio of factors for graft failure was computed. Graft survival (clear graft at last follow-up) and graft survival time were analyzed.
resultsPrior OPK failed twice in 69 (26.64%), thrice in 41 (15.83%), and >4 times in 13 (5.01%). Indications for repeat graft included rejection (83.78%), HSV (14.67%), and infection (13.90%). Pre-op IM was used in 18.91%, while post-op was in 7%. Younger age, prior therapeutic PK, corneal scars post infections, anterior segment dysgenesis, >2 quadrants deep vascularization, and >2 failed grafts increased risk of graft failure. Visual acuity improved at 1 month and declined after 3 months. 39% of grafts survived until last follow-up (mean 31.5 m), and the median survival time was 36 m (CI: 30.2 to 45.8 m).
conclusionOPK/OPK subset constitutes close to 6% of all OPKs performed, and 39% of these regrafts remain clear over a mean follow-up of 31 m. Half regrafts fail 36 m post-OPK. More than 80% of these grafts fail post rejection, and one-third post infection. Males undergo repeat OPKs more. Younger age, deep vessels, previous infections, and >2 grafts pose higher risk of failure to subsequent grafts. Current IM use is limited to 7-20% with pre-existing high risk and needs further studies to enhance graft survival in these complex situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.